External validation of a prognostic score in first-line metastastic castration-resistant prostate cancer (mCRPC)

Lorente, David; Mejorada, R. Lozano; Rueda, G AVelasco Oria De de; Hernandez, A. Sanchez; Rodrigo-Aliaga, M.; Iglesias, A.; Campayo, María de Julián; Campos, F. López; Laorden, N. Romero; Castro, Elena; Hidalgo, Daniel

doi:10.1093/annonc/mdz248.021

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We chose studies from the ClinicalTrial database and EudraCT database and some retrospective studies from the NCBI database published in the last 5 years. The selected studies explored the effect of dexamethasone (70)(71)(72)(73)(74)(75)(76), prednisone (77)(78)(79)(80)(81)(82)(83)(84)(85)(86)(87)(88)(89)(90)(91)(92)(93), and prednisolone (94) (see Table 2).…”

Section: Clinical Trials In Last 5 Yearsmentioning

confidence: 99%

A narrative review of the role of glucocorticoid receptors in prostate cancer: developments in last 5 years

Zhou¹,

Shi²,

Zhao³

et al. 2022

Transl Androl Urol

View full text Add to dashboard Cite

Background and Objective: Glucocorticoids, secreted from the adrenal gland, are commonly used in the treatment of castration-resistant prostate cancer (CRPC) because of their anti-inflammatory and antitoxic effects. However, glucocorticoids have been reported to have the opposite effects within the course of treatment. Many studies have shown that glucocorticoid receptors (GRs) are involved in the establishment of a dominant population of androgen-independent malignant cells, which may result in CRPC. In this review, we summarized the mechanisms of GRs in CRPC and the clinical application of glucocorticoids based on the present evidence. Methods:We summarized the isoforms of GRs and the mechanisms involved in CRPC. An updated literature search was performed from the ClinicalTrials database, the National Center for Biotechnology Information database and European Union Drug Regulating Authorities Clinical Trials database. The focus was on the timeframe from 2017 to 2022. At least one primary or secondary outcome [prostate-specific antigen (PSA) response rate, progression-free survival (PFS) or overall survival (OS) and median time to PSA progression] according to studies should be included.

show abstract